For more than 30 years, progressive disseminated histoplasmosis has been an AIDS-defining opportunistic infection.1 However, the infection is still widely underdiagnosed and results in many avoidable deaths.2 Diagnostic problems—due to the proteiform p...
The European Medicines Agency recently approved the updated COVID-19 mRNA vaccines developed by Pfizer–BioNTech and Moderna.1,2 The vaccines currently form part of the national immunisation programmes in many countries including Denmark. Both vaccines ...
SARS-CoV-2 viral evolution and immune evasion has reduced vaccine effectiveness. Bivalent booster doses delivering both the ancestral and BA.1/BA.5 spike fail to elicit strong omicron-specific humoral immune responses.1,2The global dominance of XBB sub...
The year 2023 marked the 25th anniversary of the first detected outbreak of Nipah virus disease. Despite Nipah virus being a priority pathogen in the WHO Research and Development blueprint, the disease it causes still carries high mortality, unchanged ...
Yang S, Yu Y, Xu Y, et al. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. Lancet Infect Dis 2023; published online Dec 15. https://doi.org/10.1016/S1473-3099(23)00744-2—In this Correspondence, the author's name should have be...
We write in response to the Comment by Wenping Gong and Jingli Du1 about our published research article on safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BC...
The SARS-CoV-2 BA.2.86 lineage, first identified in August 2023, is phylogenetically distinct from the current circulating SARS-CoV-2 omicron XBB lineages, including EG.5.1 and HK.3. Compared with XBB and BA.2, BA.2.86 carries more than 30 mutations in...
Social determinants of health are important in designing effective interventions for hepatitis B virus (HBV) infection. This systematic review characterises equity-oriented, social determinants of health-focused HBV interventions, and describes their e...
Rivera Mejía L, Peña Méndez L, Bandyopadhyay AS, et al. Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic. ...
Compared with conventional mRNA-based vaccines, self-amplifying RNA (saRNA) vaccines promise improved and longer-lived potency due to both the amplification of the RNA in vivo and the adjuvating properties of double-stranded RNA and its replication int...
Compared with conventional mRNA-based vaccines, self-amplifying RNA (saRNA) vaccines promise improved and longer-lived potency due to both the amplification of the RNA in vivo and the adjuvating properties of double-stranded RNA and its replication int...
The hospitalisation burden of RSV-associated ALRI in children younger than 5 years was significantly reduced during the first year of the COVID-19 pandemic. The rebound in hospitalisation rates to pre-pandemic rates observed in the high-income region b...
The hospitalisation burden of RSV-associated ALRI in children younger than 5 years was significantly reduced during the first year of the COVID-19 pandemic. The rebound in hospitalisation rates to pre-pandemic rates observed in the high-income region b...
In adults who had previously received three doses of an mRNA COVID-19 vaccine, immune responses 28 days after an ARCT-154 booster dose were non-inferior to those observed after a BNT162b2 booster dose for the Wuhan-Hu-1 strain of SARS-CoV-2 and superio...
In adults who had previously received three doses of an mRNA COVID-19 vaccine, immune responses 28 days after an ARCT-154 booster dose were non-inferior to those observed after a BNT162b2 booster dose for the Wuhan-Hu-1 strain of SARS-CoV-2 and superio...
Patients with haematological malignancies might develop life-threatening toxoplasmosis, especially after allogeneic haematopoietic stem-cell transplantation (HSCT). Reactivation of latent cysts is the primary mechanism of toxoplasmosis following HSCT; ...